ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
3,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
3,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4,1,Cerebral haematoma,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
5,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5,2,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
6,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,1,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
8,2,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
9,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
10,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
11,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
13,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
13,2,Ear disorder,Ear disorders NEC,Aural disorders NEC,Ear,N
13,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
13,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
13,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
14,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
15,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
15,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
15,3,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
15,4,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
16,1,Hepatocellular carcinoma,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
17,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,2,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
17,3,Viral mutation identified,Virus identification and serology,Microbiology and serology investigations,Inv,N
18,1,Delirium,Deliria,Deliria (incl confusion),Psych,N
18,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
18,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
18,4,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
18,5,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
19,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
20,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
21,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
21,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
22,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
23,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
24,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
25,1,Bleeding varicose vein,Varicose veins NEC,Venous varices,Vasc,N
25,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
26,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
27,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
27,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
28,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
29,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
31,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
32,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
36,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
36,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
37,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
37,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
39,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
40,2,Impatience,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
40,3,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
40,4,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
41,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
41,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
41,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
41,4,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,Y
41,5,Hepatic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
42,1,Abnormal dreams,Parasomnias,Sleep disorders and disturbances,Psych,N
42,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
42,3,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
43,1,Alcoholism,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
43,2,Drug abuse,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
43,3,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
44,1,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
44,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
45,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
45,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
45,3,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
46,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
46,2,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
46,3,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
47,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
47,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
47,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
48,1,Leukopenia,Leukopenias NEC,White blood cell disorders,Blood,N
48,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
48,3,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
49,1,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
49,2,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
49,3,Hepatocellular carcinoma,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
49,4,Liver transplant,Hepatic therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
49,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
49,6,Virologic failure,Infections NEC,Infections - pathogen unspecified,Infec,N
50,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
50,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
50,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
50,4,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
51,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
51,2,Genotype drug resistance test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
51,3,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
52,1,Genotype drug resistance test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
52,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
53,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
53,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
54,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
55,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
55,2,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
56,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
56,2,Genotype drug resistance test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
56,3,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
56,4,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
56,5,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
57,1,Hepatitis D RNA positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
58,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
58,2,Genotype drug resistance test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
58,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
59,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
59,2,Genotype drug resistance test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
59,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
60,1,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
60,2,Product residue present,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
60,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
60,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
61,1,Oesophageal perforation,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
61,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
61,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
62,1,Oesophageal perforation,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
62,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
62,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
63,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
63,2,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
64,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
64,2,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
65,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,2,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
67,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
67,2,Genotype drug resistance test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
67,3,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
68,1,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
68,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
68,3,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
68,4,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
68,5,Hepatocellular injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
68,6,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
68,7,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
69,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
69,2,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
69,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
69,4,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
69,5,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
69,6,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
69,7,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
69,8,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
69,9,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
